Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies

26 Oct 2024

Abstract excerpt

Abstract Background Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies. However, the use of allogeneic T cells in CAR therapy poses a challenge due to the risk of graft-versus-host disease. Recently, natural killer (NK) cells have exhibited “off‑the‑shelf” availability. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39462383
DOI: 10.1186/s40164-024-00577-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignanciesPMID 39462383Read ↗

A Novel Natural Killer Cell Expansion Technology for the Development of Cellular ImmunotherapiesSemantic proximity Read ↗

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challengesSemantic proximity Read ↗

A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?Semantic proximity Read ↗

The Application of Nanobody in CAR-T TherapySemantic proximity Read ↗

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advancesSemantic proximity Read ↗

Nanobody-based CAR-T cells for cancer immunotherapySemantic proximity Read ↗

Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorderSemantic proximity Read ↗

Current status and perspective of CAR-T and CAR-NK cell therapy trials in GermanySemantic proximity Read ↗

Chimeric antigen receptor-natural killer cell therapy: a new force in intrinsic immunotherapy for cancer treatmentSemantic proximity Read ↗

Natural Born Killers: NK Cells in Cancer TherapySemantic proximity Read ↗

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read ↗

Natural killer cell engineering for cellular therapy of cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.